ALIM
- Alimera Sciences, Inc.
()
Overview
Company Summary
Alimera Sciences, Inc. is a pharmaceutical company that focuses on developing and commercializing innovative treatments for eye diseases. The company specializes in the field of ophthalmology and is primarily engaged in the research, development, and sale of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases.
Alimera Sciences' flagship product is called ILUVIEN�, an implantable drug delivery system approved for the treatment of diabetic macular edema (DME). DME is a condition that affects people with diabetes and can lead to vision loss or blindness if left untreated. ILUVIEN� is designed to continuously release a corticosteroid called fluocinolone acetonide within the eye, reducing inflammation and improving vision in DME patients.
The company's mission is to provide innovative and effective therapies for retinal diseases. Alimera Sciences leverages its expertise in drug delivery and ophthalmology to develop and enhance existing treatments for various eye conditions, while also conducting clinical trials to explore potential new therapies.
In addition to its focus on diabetic macular edema, Alimera Sciences is involved in researching other retinal diseases, such as age-related macular degeneration (AMD) and retinal vein occlusion (RVO). By continuously advancing its product portfolio and scientific knowledge, the company aims to improve the quality of life for individuals affected by these sight-threatening diseases.
Overall, Alimera Sciences, Inc. operates as a pharmaceutical company dedicated to providing innovative solutions and treatments to patients suffering from retinal diseases, with a specific focus on diabetic macular edema.